{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"ketamine-induced-biliary-dilatation","columns":[{"gene":"","key":"population-90f7d5465475f35f1a94","label":"Ketamine-induced biliary dilatation","mondoId":"MONDO:0017394","onsetQualifier":null,"originColumnKey":"MONDO:0017394/ORPHA:293807","originalViews":[{"key":"MONDO:0017394/ORPHA:293807","label":"Ketamine-induced biliary dilatation","scopeLabel":"ORPHA:293807","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["185dd822a149f1a59636be87a04b3e1e76c656601da50dfd9117cc6103c76f85","1e7b3e6e2ddc8e99e23d81ff53837d324a940f7f0d3d30c800e7773d11606855","73d305f09203f0e3aadf02923c2d6cf4db78b08c691f2fa5cd09e5bfaa6d8933","feb2fa484155e3f4883922a0b4e19e1274f8a35c55228aa920a9dfbd3dff8bab"],"recordQualifiers":{},"scopeLabel":"ORPHA:293807","sourceIds":["ORPHA:293807"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-90f7d5465475f35f1a94"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0002027","HP:0012440","HP:0100518","HP:0000738"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":4,"sourceGroups":{"orphanet":4}},"features":[{"hpoId":"HP:0002027","label":"Abdominal pain","primary":true},{"hpoId":"HP:0012440","label":"Abnormal biliary tract morphology","primary":true},{"hpoId":"HP:0100518","label":"Dysuria","primary":true},{"hpoId":"HP:0000738","label":"Hallucinations","primary":true}],"ledeHtml":"Ketamine-induced biliary dilatation is an acquired biliary tract disease caused by the abusive consumption of ketamine, which results in the fusiform dilatation of the common bile ducts (CBD) without obstructive lesions or dilatation of the intrahepatic biliary ducts. Possible manifestations of the underlying cholangiopathy include epigastric pain and impaired liver function. Severity of CBD dilatation appears to correlate with the duration of ketamine consumption and the condition has been reported to be reversible in abstinent patients.","mondoId":"MONDO:0017394","node":{"canonicalSlug":"ketamine-induced-biliary-dilatation","comparisons":[{"documentSha256":"f9c061b460ad24cce04d2ecb1a8f69346cdb4351c5b357c2261618b45460ab75","key":"legacy-ketamine-induced-biliary-dilatation","kind":"legacy","label":"ketamine-induced biliary dilatation","memberIds":["MONDO:0017394"],"mondoId":"MONDO:0017394","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/ketamine-induced-biliary-dilatation.f9c061b460ad24cce04d2ecb1a8f69346cdb4351c5b357c2261618b45460ab75.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","matchMethod":"same-ontology-node","name":"ketamine-induced biliary dilatation","paragraphs":["Ketamine-induced biliary dilatation is an acquired biliary tract disease caused by the abusive consumption of ketamine, which results in the fusiform dilatation of the common bile ducts (CBD) without obstructive lesions or dilatation of the intrahepatic biliary ducts. Possible manifestations of the underlying cholangiopathy include epigastric pain and impaired liver function. Severity of CBD dilatation appears to correlate with the duration of ketamine consumption and the condition has been reported to be reversible in abstinent patients."],"scope":"exact","source":"MONDO","upstream":"Orphanet:293807","url":"https://monarchinitiative.org/MONDO:0017394"},"ownColumnKeys":["population-90f7d5465475f35f1a94"],"publication":"published","relationships":[{"kind":"parent","label":"biliary tract disorder","mondoId":"MONDO:0004868","slug":null},{"kind":"parent","label":"poisoning","mondoId":"MONDO:0029000","slug":null}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"range","key":"185dd822a149f1a59636be87a04b3e1e76c656601da50dfd9117cc6103c76f85","raw":{"aspect":"P","body_system":"digestive","disease_id":"ORPHA:293807","disease_name":"Ketamine-induced biliary dilatation","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0012440","is_excluded":false,"label":"Abnormal biliary tract morphology","onset_id":null,"reference":"ORPHA:293807","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"1e7b3e6e2ddc8e99e23d81ff53837d324a940f7f0d3d30c800e7773d11606855","raw":{"aspect":"P","body_system":"other","disease_id":"ORPHA:293807","disease_name":"Ketamine-induced biliary dilatation","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0002027","is_excluded":false,"label":"Abdominal pain","onset_id":null,"reference":"ORPHA:293807","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"73d305f09203f0e3aadf02923c2d6cf4db78b08c691f2fa5cd09e5bfaa6d8933","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:293807","disease_name":"Ketamine-induced biliary dilatation","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0100518","is_excluded":false,"label":"Dysuria","onset_id":null,"reference":"ORPHA:293807","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"feb2fa484155e3f4883922a0b4e19e1274f8a35c55228aa920a9dfbd3dff8bab","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:293807","disease_name":"Ketamine-induced biliary dilatation","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000738","is_excluded":false,"label":"Hallucinations","onset_id":null,"reference":"ORPHA:293807","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0017394\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>same-ontology-node</dd><dt>Upstream attribution</dt><dd>Orphanet:293807</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Ketamine-induced biliary dilatation is an acquired biliary tract disease caused by the abusive consumption of ketamine, which results in the fusiform dilatation of the common bile ducts (CBD) without obstructive lesions or dilatation of the intrahepatic biliary ducts. Possible manifestations of the underlying cholangiopathy include epigastric pain and impaired liver function. Severity of CBD dilatation appears to correlate with the duration of ketamine consumption and the condition has been reported to be reversible in abstinent patients.</p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0017394\" rel=\"noreferrer\">MONDO</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"ketamine-induced-biliary-dilatation","sourceDocuments":[{"name":"MONDO: ketamine-induced biliary dilatation","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0017394"}],"sourceNote":"","synonyms":[],"takeawayHtml":"","title":"ketamine-induced biliary dilatation"},"schemaVersion":1}
